We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AnaSpec Introduces Industry’s First NMHC II Antibodies
Product News

AnaSpec Introduces Industry’s First NMHC II Antibodies

AnaSpec Introduces Industry’s First NMHC II Antibodies
Product News

AnaSpec Introduces Industry’s First NMHC II Antibodies


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "AnaSpec Introduces Industry’s First NMHC II Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AnaSpec has announced the release of the industry’s first provider of nonmuscle myosin class II heavy chain (NMHC) antibodies.

Nonmuscle myosin class II proteins belong to the superfamily of actin-based motor proteins. They form hexamer structures composed of two ~200kDa heavy chains (NMHC II) and two pairs of 20kDa and 17kDa light chains (MLC20 and MLC17). Nonmuscle myosins are classified according to the heavy chain isoforms; light chains are conserved.

Three different isoforms that share 64-80% amino acid sequence identity have been detected in mammals: NMHC II-A, NMHC II-B, and NMHC II-C. Although NMHC II molecules have now been found in muscle cells as well, the name “nonmuscle myosin” was already widespread and is in use today. NMHC II-A is most abundant compared to other NMHC isoforms in human lung, spleen, thymus, uterus, and colon. Thus, single amino acid mutation in MNMH II-A results in kidney and platelet defects in humans. In addition, recent study indicates that replacement of NMHC II-B with NMHC II-A rescues brain defect in mice.
Advertisement